CAR-T cell therapy for warm antibody autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new treatment using your own immune cells, modified to target and destroy the faulty cells causing your anemia. It aims to provide a lasting remission for people whose disease has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have warm antibody autoimmune hemolytic anemia that has come back or not improved after standard treatments like steroids, rituximab, or cyclophosphamide.
- Your disease has lasted more than 6 months and is still active despite at least 2 months of treatment.
- You have no active infections and your blood counts, liver, kidney, and heart functions are within acceptable levels.
- You must not have had certain treatments like plasma exchange or IVIG within the last 2 weeks, and no live vaccines within 8 weeks before the CAR-T infusion.
- You must agree to use effective contraception and not donate sperm or eggs during the study and for 2 years after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
This early-phase trial tests a new cell therapy (UCAR T cells) that targets specific markers on your immune cells (called CD19 and BCMA) to help stop your body from attacking your own red blood cells. It's for people with autoimmune hemolytic anemia that hasn't responded to multiple standard treatments.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Hear when a new Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.